Találati lista | Tudóstér

001-es BibID:	BIBFORM010928
Első szerző:	Miheller Pál
Cím:	Efficacy and safety of infliximab induction therapy in Crohn's disease in Central Europe : a Hungarian nationwide observational study / Pál Miheller, Péter L. Lakatos, Gábor Horváth, Tamás Molnár, Tamás Szamosi, Zsófia Czeglédi, Ágnes Salamon, József Czimmer, György Rumi, Károly Palatka, Mária Papp, Zsolt Jakab, Andrea Szabó, András Gelley, László Lakatos, Zsolt Barta, Csaba Balázs, István Rácz, Margit Zeher, Zoltán Döbrönte, István Altorjay, Béla Hunyady, László Simon, János Papp, János Banai, Ferenc Nagy, János Lonovics, László Újszászy, Györgyi Műzes, László Herszényi, Zsolt Tulassay
Dátum:	2009
ISSN:	1471-230X (Electronic)
Megjegyzések:	Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nationwide, multicenter experience with IFX induction therapy for CD in Hungary. Methods: During a 6-year-period, beginning in 2000, a total of 363 CD patients were treated with IFX as induction therapy (5 mg/kg IFX infusions given at week 0, 2 and 6) at eleven centers in Hungary in this observational study. Data analysis included patient demographics, important disease parameters and the outcome of IFX induction therapy. Results: Three hundred and sixty three patients (183 women and 180 men) were treated with IFX since 2000. Mean age was 33.5 ? 11.2 years and the mean duration of disease was 6.7 ? 6.1 years. The population included 114 patients (31.4%) with therapy-refractory CD, 195 patients (53.7%) with fistulas, 16 patients (4.4%) with both therapy-refractory CD and fistulas, and 26 patients (7.2%) with steroid dependent CD. Overall response rate was 86.2% (313/363). A higher response rate was observed in patients with shorter disease duration (p = 0.05, OR:0.54, 95%CI:0.29-0.99) and concomitant immunosuppressant therapy (p = 0.05, OR: 2.03, 95%CI:0.165-0.596). Concomitant steroid treatment did not enhance the efficacy of IFX induction therapy. Adverse events included 34 allergic reactions (9.4%), 17 delayed type hypersensitivity (4.7%), 16 infections (4.4%), and 3 malignancies (0.8%). Conclusion: IFX was safe and effective treatment in this cohort of Hungarian CD patients. Based on our experience co-administration of immunosuppressant therapy is suggested in patients receiving IFX induction therapy. However, concomitant steroid treatment did not enhanced the efficacy of IFX induction therapy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	BMC Gastroenterology. - 9 : 6 (2009), p. 66-73. -
További szerzők:	Lakatos Péter (Semmelweis Egyetem) Horváth Gábor Molnár Tamás (orvos) Szamosi Tamás Czeglédi Zsófia Salamon Ágnes (orvos Szekszárd) Czimmer József Rumi György Jr. Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Jakab Zsolt (orvos Szombathely) Szabó Andrea (orvos Győr) Gelley András Lakatos László (orvos Budapest) Barta Zsolt (1964-) (belgyógyász, gasztroenterológus) Balázs Csaba Rácz István (orvos Győr) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Döbrönte Zoltán Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Hunyady Béla Simon László (orvos Szekszárd) Papp János (orvos Veszprém) Banai János Nagy Ferenc (orvos Szeged) Lonovics János (Szeged) Újszászy László Műzes Györgyi Herszényi László Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM037073
Első szerző:	Rácz István (orvos Győr)
Cím:	Management of Peptic Ulcer Bleeding in Different Case Volume Workplaces: Results of a Nationwide Inquiry in Hungary / Rácz István, Kárász Tibor, Lukács Krisztina, Rácz Ferenc, Kersák János, Wacha Judit, Szalóki Tibor, Szász Magdolna, Gyenes István, Altorjay István
Dátum:	2012
ISSN:	1687-6121
Megjegyzések:	The aim of this study was to conduct a national survey to evaluate the recent endoscopic treatment and drug therapy of pepticulcer bleeding (PUB) patients and to compare practices in high and low case volume Hungarian workplaces. A total of 62gastroenterology units participated in the six-month study. A total of 3033 PUB cases and a mean of 8.15 ? 3.9 PUB cases permonth per unit were reported. In the 23 high case volume units (HCV), there was a mean of 12.9?5.4 PUB cases/month, whereasin the 39 low case volume units (LCV), a mean of 5.3 ? 2.9 PUB cases/month were treated during the study period. In HCVunits, endoscopic therapies for Forrest Ia, Ib, and IIa ulcers were significantly more often used than in LCV units (86% versus68%; P = 0.001). Among patients with stigmata of recent haemorrhage (Forrest I, II), bolus + continuous infusion PPI was givensignificantly more frequently in HCV than in LCV units (49.6% versus 33.2%; P = 0.001).Mortality in HCV units was less than inLCV units (2.7% versus 4.3%; P = 0.023). The penetration of evidence-based recommendations for PUB management is strongerin HCV units resulting lower mortality.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban peptic ulcer bleeding PUB high case volume units LCV units
Megjelenés:	Gastroenterology Research and Practice 2012 (2012), p. Article ID 956434. -
További szerzők:	Kárász Tibor Lukács Krisztina Rácz Ferenc Kersák János Wacha Judit Szalóki Tibor Szász Magdolna Gyenes István Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM036076
035-os BibID:	PMID:19637334
Első szerző:	Reinisch, Walter
Cím:	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study / Walter Reinisch, Williem de Villiers, László Bene, László Simon, István Rácz, Seymour Katz, István Altorjay, Brian Feagan, Dennis Riff, Charles N. Bernstein, Daniel Hommes, Paul Rutgeerts, Antoine Cortot, Michael Gaspari, May Cheng, Tillman Pearce, Bruce E. Sands
Dátum:	2010
ISSN:	1078-0998
Megjegyzések:	BACKGROUND: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms. METHODS: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels. RESULTS: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%-38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C-reactive protein levels. The overall frequency of adverse events was similar in all groups (58%-75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab. CONCLUSIONS: Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Inflammatory Bowel Diseases 16 : 2 (2010), p. 233-42. -
További szerzők:	Villiers, Williem de Bene László (Budapest) Simon László (orvos Szekszárd) Rácz István (orvos Győr) Katz, Seymour Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Feagan, Brian Riff, Dennis Bernstein, Charles N. Hommes, Daniel Rutgeerts, Paul Cortot, Antoine Gaspari, Michael Cheng, May Pearce, Tillman Sands, Bruce E.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: